Thiazolidinediones (TZDs), such as rosiglitazone and pioglitazone, activate peroxisome proliferator-activated receptor gamma (PPAR-), a nuclear receptor that regulates genes involved in glucose and lipid metabolism, thereby improving insulin sensitivity in T2DM
Lilly's TRIUMPH clinical program includes multiple Phase III trials evaluating retatrutide across different patient populations and endpoints: Seven additional Phase III readouts are expected throughout 2026, covering populations with type 2 diabetes, cardiovascular disease, obstructive sleep apnea, and other obesity-related comorbidities Cardiovascular outcomes data the gold standard for demonstrating that weight loss translates into reduced heart attacks, strokes, and cardiovascular death will be critical for retatrutide's regulatory and commercial positioning Head-to-head trials comparing retatrutide directly to existing therapies may provide definitive comparative efficacy data The Drug vs
Cardiac and skeletal muscle myocyte metabolism is largely oxidative and dependent on free fatty acid delivery and mitochondrial transport
Abstract Fibromyalgia (FM) is a disease primarily associated with chronic widespread pain, but other common symptoms are anxiety and depression
